#7 - Predictive Oncology (NASDAQ:POAI)
With a market cap of just over $3 billion, Predictive Oncology Inc. (NASDAQ: POAI) classifies as a mid-cap stock. However, with the stock trading below $1, it also falls into the category of penny stocks.
Predictive Oncology is similar to Schrodinger in that it uses AI to assist the drug discovery process. However, as the company’s name points out, its sole focus is on finding and developing better cancer treatments. To do so, the company uses its PEDAL active learning platform. Predictive Oncology has 11 drugs on the market, with approximately 180 in development.
That said, this is a company that is not currently profitable and generating very little revenue. POAI stock is down approximately 72% in 2024, which makes it one of the worst-performing stocks in that period. It also has issued a "going concern" warning, meaning there is significant doubt about the company's ability to continue operating over the next 12 months without taking drastic measures like restructuring, obtaining additional financing, or selling assets. Simply put, it’s a shot in the dark. But with demand for new oncology treatments continuing to grow, it may be worth a speculative investment.
About Predictive Oncology
Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.
Read More - Current Price
- $0.88
- Consensus Rating
- Buy
- Ratings Breakdown
- 1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $3.00 (240.9% Upside)
In addition to the catalysts we mentioned in this presentation, another reason to consider investing in these medical stocks is their defensive qualities. Consumers may be able to trade down for certain products, but when it comes to their health insurance and their prescriptions, they typically won't compromise. This gives these companies a stable revenue base.
However, investors want more than just stability, they also want growth - and the companies on this list have many catalysts for future growth. Medical technology (med tech) on both the hardware and software side will continue to be a relevant and growing field with the continued emergence of AI.
If you want to do more research on one or more of the stocks in this presentation, or if you're looking for other medical stocks, MarketBeat provides investors with an updated list of the largest 50 medical stocks. This allows you to review pertinent information about these companies, including recent earnings reports, analyst forecasts, an interactive stock price chart and more.
More Investing Slideshows:
